Our patented technology delivers a step change in sensitivity and selectivity enabling new biomarkers to be measured within minutes in finger-prick samples of unprocessed whole blood. These sensors are low cost, single-use biosensors with a portable handheld reader creating new point-of-care diagnostics not previously possible.
Our initial focus are the purines, the earliest detectable biomarkers of cell/tissue hypoxia and ischaemia. Changes to blood purine levels occur because of acute injuries such as stroke, traumatic brain injury (TBI), heart attacks, foetal hypoxia and limb ischaemia. Purine levels provide a valuable clinical insight into underlying pathology and prognosis, and can be used – from the earliest point of injury – in decisions regarding the administration of a timely course of treatment, and in the monitoring of treatment outcomes.